Skip to main content

WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.

Publication ,  Journal Article
Rein, LAM; Chao, NJ
Published in: Expert Opin Investig Drugs
March 2014

INTRODUCTION: The Wilms tumor 1 (WT1) gene was originally identified as a tumor suppressor gene that, when mutated, would lead to the development of pediatric renal tumors. More recently, it has been determined that WT1 is overexpressed in 90% of patients with acute myeloid leukemia (AML) and is mutated in approximately 10% of AML patients. WT1 plays a role in normal hematopoiesis and, in AML specifically, it has oncogenic function and plays an important role in cellular proliferation and differentiation. The ubiquity of WT1 in leukemia has lead to the development of vaccines aimed at employing the host immune system to mount a T-cell response to a known antigen. AREAS COVERED: In this evaluation, the authors discuss the role of WT1 in normal hematopoiesis as well as in the development of hematologic malignancies. Furthermore, the authors discuss the data supporting the development of WT1 vaccines, and the clinical trials supporting their use in patients with acute leukemia. EXPERT OPINION: Several small trials have been conducted which support the safety and efficacy of this therapy, although larger trials are certainly warranted. In the authors' opinion, the WT1 vaccination has potential in terms of its application as an adjuvant therapy for patients with AML who are at high risk of relapse or who have detectable minimal residual disease after initial standard therapy.

Duke Scholars

Published In

Expert Opin Investig Drugs

DOI

EISSN

1744-7658

Publication Date

March 2014

Volume

23

Issue

3

Start / End Page

417 / 426

Location

England

Related Subject Headings

  • WT1 Proteins
  • Vaccines, Subunit
  • Pharmacology & Pharmacy
  • Leukemia, Myeloid, Acute
  • Immunotherapy, Adoptive
  • Humans
  • Genes, Wilms Tumor
  • Cancer Vaccines
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rein, L. A. M., & Chao, N. J. (2014). WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy. Expert Opin Investig Drugs, 23(3), 417–426. https://doi.org/10.1517/13543784.2014.889114
Rein, Lindsay A. M., and Nelson J. Chao. “WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.Expert Opin Investig Drugs 23, no. 3 (March 2014): 417–26. https://doi.org/10.1517/13543784.2014.889114.
Rein LAM, Chao NJ. WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy. Expert Opin Investig Drugs. 2014 Mar;23(3):417–26.
Rein, Lindsay A. M., and Nelson J. Chao. “WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.Expert Opin Investig Drugs, vol. 23, no. 3, Mar. 2014, pp. 417–26. Pubmed, doi:10.1517/13543784.2014.889114.
Rein LAM, Chao NJ. WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy. Expert Opin Investig Drugs. 2014 Mar;23(3):417–426.

Published In

Expert Opin Investig Drugs

DOI

EISSN

1744-7658

Publication Date

March 2014

Volume

23

Issue

3

Start / End Page

417 / 426

Location

England

Related Subject Headings

  • WT1 Proteins
  • Vaccines, Subunit
  • Pharmacology & Pharmacy
  • Leukemia, Myeloid, Acute
  • Immunotherapy, Adoptive
  • Humans
  • Genes, Wilms Tumor
  • Cancer Vaccines
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences